stock is up over 15

Discussion in 'Amylin' started by Anonymous, Dec 17, 2010 at 4:35 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    what's going on?
     

  2. Anonymous

    Anonymous Guest

    Hint: Employees learning Japanese. Rosetta Stone and Benihana for the Holidays.
     
  3. Anonymous

    Anonymous Guest

    3 times the usual exchange volume. Here come Santa. Be sure to leave some organic cookies and milk out.
     
  4. Anonymous

    Anonymous Guest

    Negotiations with FDA going very well but keep it quiet! Lets all load up on amln and alks in the interim
     
  5. Anonymous

    Anonymous Guest

    The goal is to get it to $25 by Christmas Day.
     
  6. Anonymous

    Anonymous Guest

    Spectacular turn around and going much higher next week. Great gift idea for my large family.
     
  7. Anonymous

    Anonymous Guest

    Bonus and merit increase will be in Yen.
     
  8. Anonymous

    Anonymous Guest

    Quiet indeed as this is not the alkermes board
     
  9. Anonymous

    Anonymous Guest

    Sure but alkermes is better value and less risk

    ALKS has a superior balance sheet and trades just above book value. Add a better pipeline and smart money buys alks
     
  10. Anonymous

    Anonymous Guest

    Hang on to what you have. More upturn on the way. Should reach another high by New Year's day.
     
  11. Anonymous

    Anonymous Guest

    A fantastic surprise is on the way. It will be a spectacular end that will lead to many new beginnings next year. Splendid stocking stuffers!
     
  12. Anonymous

    Anonymous Guest

    Buyout.... Things To Consider.... 18-Dec-10 10:21 pm
    1) Amylin is not desperate to do a deal today and can ride out the current Bydureon approval delay.

    2) Buyout $ price offer is the most important factor Amylin will need to consider.

    3) A Takeda deal would allow Amylin to survive and operate as a subsidiary company under Takeda, keep their name, retain employees, retain management and most important keep their R&D culture and programs alive.

    4) A Lilly deal would mark the end of Amylin.

    5) Lilly would benefit by capturing the entire Exenatide franchise for themselves and share part of obesity with Takeda.

    6) Takeda would benefit by capturing Amylin's entire obesity franchise and will once again have them join hands with Lilly to co-promote the Exenatide franchise.

    7) A third party bid for Amylin will be interesting to see happen and will be driven by the perceived value Amylin's share of the Lilly and Takeda will bring to the acquirer.

    8) A bidding war is also very possible and would be a welcome happening for Amylin Shareholders.

    JMO
    Kevinmik
     
  13. Anonymous

    Anonymous Guest

    Awesome! Stuff my stockings even more this Holidays!!!!!
     
  14. Anonymous

    Anonymous Guest

    You nailed it that alks represents superior value and the preferred way to play the byuderon wild card.
     
  15. Anonymous

    Anonymous Guest

    Talks about adding Palin to the Board. The popularity of Palin will bring new investors from the Tea Party and Republican base. She's an important figure and could organicly transform healthcare. A maverick is needed now.
     
  16. Anonymous

    Anonymous Guest

    Re: stock is up over 15 Pump and dump

    someone is selling.I hope it is not Icahn or Fidelity
     
  17. Anonymous

    Anonymous Guest

    and alkermes has an outstanding management team
     
  18. Anonymous

    Anonymous Guest

    Right and alks shares were up nicely yesterday while amy shares were down again
     
  19. Anonymous

    Anonymous Guest

    Alks is a well managed and professional company.